TRex Bio (NASDAQ:TRXB) Stock Rated “Buy” in New Coverage at Stifel Nicolaus

Analysts at Stifel Nicolaus started coverage on shares of TRex Bio (NASDAQ:TRXB) in a report released on Tuesday, Briefing.com reports. The brokerage set a “buy” rating and a $39.00 price target on the stock. Stifel Nicolaus‘s target price would indicate a potential upside of 185.92% from the company’s previous close.

Several other research firms also recently weighed in on TRXB. JPMorgan Chase & Co. initiated coverage on TRex Bio in a research report on Tuesday. They set an “overweight” rating and a $20.00 target price on the stock. Wedbush assumed coverage on TRex Bio in a research note on Monday. They issued an “outperform” rating and a $30.00 price target on the stock. Four research analysts have rated the stock with a Buy rating. According to data from MarketBeat.com, TRex Bio currently has an average rating of “Buy” and an average price target of $29.67.

TRex Bio Stock Performance

TRXB stock opened at $13.64 on Tuesday. TRex Bio has a 52-week low of $13.10 and a 52-week high of $16.56.

Insiders Place Their Bets

In related news, major shareholder Alexandria Venture Investments purchased 178,571 shares of the business’s stock in a transaction on Tuesday, October 13th. The shares were bought at an average price of $14.00 per share, with a total value of $2,499,994.00. Following the completion of the purchase, the insider directly owned 1,346,501 shares in the company, valued at approximately $18,851,014. This trade represents a 15.29% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink.

TRex Bio Company Profile

We are a clinical-stage biopharmaceutical company focused on tissue Treg biology for the discovery and development of immunoregulatory medicines designed to restore immune balance and promote tissue repair to address unmet needs of patients with autoimmune and inflammatory diseases. TRexBio was built on a pivotal scientific insight: that regulatory T cells (“Tregs”) in human tissue are not merely passive suppressors of inflammation, but active orchestrators of tissue immune homeostasis and repair.